Actively Recruiting
Phase 3 Randomized Study Comparing Xaluritamig Plus Abiraterone to Investigators Choice Treatments in Men With Chemotherapy-naefve Metastatic Castration-resistant Prostate Cancer
Led by Amgen · Updated on 2026-10-20
750
Participants Needed
159
Research Sites
138 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to compare overall survival in men with chemotherapy-naefve metastatic castration-resistant prostate cancer. The study evaluates the combination of xaluritamig and abiraterone against the investigators choice of treatments, which include abiraterone, docetaxel, or cabazitaxel. The trial is a phase 3, open-label, randomized study sponsored by Amgen. Participants will be randomly assigned to receive either xaluritamig administered intravenously combined with oral abiraterone acetate, or the investigators choice of one of the following treatments daily oral abiraterone acetate, or intravenous docetaxel or cabazitaxel given every three weeks. Treatments continue with regular monitoring throughout the study period, which lasts up to approximately 51 months for outcome assessments. Participants will undergo various assessments including imaging scans such as CT, MRI, or bone scans to confirm metastatic disease and monitor progression. Researchers will also evaluate pain levels, quality of life, prostate-specific antigen PSA responses, and adverse events throughout the study. Follow-up evaluations will continue for up to 51 months to measure survival and other health outcomes, with safety monitoring conducted throughout the participation period.
CONDITIONS
Brief Title
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Research Team
A
Amgen Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here